D-erythro-Sphingosine (Synonyms: Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)

Name: D-erythro-Sphingosine
Brand: MedChemExpress
SKU: HY-101047
Rating: 5.0 (4 reviews)

Cat. No.: HY-101047 Pureza: 98.0%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC₅₀ of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 123-78-4

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
500 mg	En stock	Estimated Time of Arrival: December 31
1 g	En stock	Estimated Time of Arrival: December 31
5 g	En stock	Estimated Time of Arrival: December 31
10 g	Obtener un presupuesto
50 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 4 publication(s) in Google Scholar

Other Forms of D-erythro-Sphingosine:

D-erythro-Sphingosine-d₇ In-stock
D-erythro-Sphingosine hydrochloride In-stock
D-erythro-Sphingosine (Standard) In-stock
D-erythro-Sphingosine-¹³C₂,d₂ Obtener un presupuesto

4 Publications Citing Use of MCE D-erythro-Sphingosine

Bio/Physico-chemical Assay

RT-PCR

: D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 19;15(1):8221. [Abstract]; D-erythro-Sphingosine (10 μM, 30 min). Effects of sph addition in different ways in ZIKV-infected cells. The protein levels were quantified using western blot at 48 h post infection. Con.: DMSO treatment.

: D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 19;15(1):8221. [Abstract]; D-erythro-Sphingosine (10 μM, 30 min). Effects of sph addition in different ways in ZIKV-infected cells. ZIKV mRNA levels were examined using qPCR (b; n = 3 biologically independent cell samples; two-sided multiple unpaired t-test) at 48 h post infection. Con.: DMSO treatment.

: D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]; Primary cells were treated with solvent, 5 μM of sphingosine, 10 μM of DASA58 plus sphingosine, and 200 nM of cerulein plus 10 ng/mL of LPS and DASA58 with LPS and sphingosine for 6 h. Cells were lysed for trypsin assay.

: D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]; Primary cells were treated with solvent, 5 μM of sphingosine, 10 μM of DASA58 plus sphingosine, and 200 nM of cerulein plus 10 ng/mL of LPS and DASA58 with LPS and sphingosine for 6 h. Cells were lysed for cathepsin B assay by WB.

: D-erythro-Sphingosine purchased from MedChemExpress. Usage Cited in: Mol Med. 2022 Sep 6;28(1):106. [Abstract]; Acid ceramidase (ASAH1) regulated the activity of trypsin and cathepsin B through sphingosine (SPH). Lentivirus particles containing nontargeting shRNA/Control vector or shRNA targeting ASAH1/ASAH1 expressing plasmid were added to primary pancreatic acinar cells. Additionally, the cells were treated as indicated. Cathepsin B activity was detected by a spectrophotometer.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PKC:

Ver todas las isoformas

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

Ver todos los productos específicos de isoformas Endogenous Metabolite:

Ver todas las isoformas

Human Endogenous Metabolite Microbial Metabolite

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

IC₅₀ & Target^[1]^[2]^[3]^[4]

p32

8 μM (EC₅₀)

PKC

PP2A

Human Endogenous Metabolite

Microbial Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
FL5.12	IC₅₀	3.6 3 Compound: 6	Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis	[PMID: 27475534]
FL5.12	IC₅₀	3.6 3 Compound: 6	Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis	[PMID: 27475534]
FL5.12	IC₅₀	3.6 3 Compound: 6	Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis	[PMID: 27475534]
Jurkat	IC₅₀	3.48 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.01 3 Compound: Sphingosine	Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.88 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.88 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	3.38 3 Compound: Sphingosine	Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	3.38 3 Compound: Sphingosine	Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.01 3 Compound: Sphingosine	Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	3.48 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.01 3 Compound: Sphingosine	Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	2.88 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	3.38 3 Compound: Sphingosine	Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]
Jurkat	IC₅₀	3.48 3 Compound: Sphingosine	Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay	[PMID: 17400555]

In Vitro

A p32-sphingosine-activated protein kinase responds to low concentrations of D-erythro-Sphingosine with an initial activation observed at 2.5 μM and a peak activity at 10-20 μM. This kinase shows a modest specificity for D-erythro-Sphingosine over other sphingosine tereoisomers, and a preference for sphingosines over ihydrosphingosines^[1]. D-erythro-Sphingosine inhibits protein kinase C in vitro^[2]. D-erythro-Sphingosine has been shown to inhibit protein kinase C, which affects cell regulation and several signal transduction pathways, and exhibits antitumor promoter activities in various mammalian cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

299.49

Fòrmula

C₁₈H₃₇NO₂

No. CAS

123-78-4

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO

Structure Classification

Others

Initial Source

Endogenous metabolite

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (166.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3390 mL	16.6950 mL	33.3901 mL
5 mM	0.6678 mL	3.3390 mL	6.6780 mL
10 mM	0.3339 mL	1.6695 mL	3.3390 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 98.0%

Select Batch:

Ficha de datos (269 KB) SDS (393 KB)

COA (239 KB) HNMR (247 KB) MS (204 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703. [Content Brief]

[2]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91. [Content Brief]

[3]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7. [Content Brief]

[4]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3390 mL	16.6950 mL	33.3901 mL	83.4752 mL
	5 mM	0.6678 mL	3.3390 mL	6.6780 mL	16.6950 mL
	10 mM	0.3339 mL	1.6695 mL	3.3390 mL	8.3475 mL
	15 mM	0.2226 mL	1.1130 mL	2.2260 mL	5.5650 mL
	20 mM	0.1670 mL	0.8348 mL	1.6695 mL	4.1738 mL
	25 mM	0.1336 mL	0.6678 mL	1.3356 mL	3.3390 mL
	30 mM	0.1113 mL	0.5565 mL	1.1130 mL	2.7825 mL
	40 mM	0.0835 mL	0.4174 mL	0.8348 mL	2.0869 mL
	50 mM	0.0668 mL	0.3339 mL	0.6678 mL	1.6695 mL
	60 mM	0.0557 mL	0.2783 mL	0.5565 mL	1.3913 mL
	80 mM	0.0417 mL	0.2087 mL	0.4174 mL	1.0434 mL
	100 mM	0.0334 mL	0.1670 mL	0.3339 mL	0.8348 mL

D-erythro-Sphingosine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

D-erythro-Sphingosine123-78-4Erythrosphingosine erythro-C18-Sphingosine trans-4-SphingeninePKCPhosphataseEndogenous MetaboliteProtein kinase CInhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

D-erythro-Sphingosine (Synonyms: Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)

Revisión del cliente

Other Forms of D-erythro-Sphingosine:

D-erythro-Sphingosine Related Antibodies

4 Publications Citing Use of MCE D-erythro-Sphingosine

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PKC:

Ver todos los productos específicos de isoformas Endogenous Metabolite:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

D-erythro-Sphingosine Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

D-erythro-Sphingosine Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report